Shkreli's Retrophin Eyes Public Markets to Fund Rare Diseases
Martin Shkreli has never been one to go with the flow. The hedge fund manager at MSMB Capital Management is known for activism: He helped derail the proposed merger between AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc., fought Pfizer Inc.'s decision to replace CEO Jeff Kindler with an insider and has pushed out several health care CEOs he felt weren't doing their jobs.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST